TherapeuticsMD (NSDQ:TXMD) is negotiating with the FDA over the proposed label for its investigational, applicator-free estradiol vaginal capsule, TX-004HR, the company reported today.
The softgel capsule is designed to treat moderate-to-severe vaginal pain experienced during sex, a symptom of vulvar and vaginal atrophy in women who have undergone menopause.
Get the full story at our sister site, Drug Delivery Business News.
The post TherapeuticsMD negotiates label for vaginal capsule after NDA resubmission appeared first on MassDevice.